Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 1

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors

NCT ID: NCT06480552Sponsor: Teva Branded Pharmaceutical Products R&D LLCLast updated: 2026-06-04

Summary

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Determine a RP2D of TEV-56278 in combination with pembrolizumab The secondary objectives of this trial are to: * Characterize the serum pharmacokinetics of TEV-56278 * Evaluate the antitumor activity of TEV-56278 * Determine the safety and tolerability of TEV-56278 * Evaluate other measures of antitumor activity of TEV-56278 * Evaluate anti-tumor activity Participants will be treated up to 12 months with a follow-up period of up to 12 months after last infusion. The total duration of the trial will be up to 25 months for individual participants. Participants who exhibit a favorable benefit risk profile at the end of the 12 month trial treatment period may be offered an opportunity for an extended treatment period in which they can be treated for a maximum of 12 additional months (up to 26 additional cycles of TEV-56278).

Arms & interventions

  • DrugTEV-56278

    Administered intravenously

  • DrugPembrolizumab

    Administered intravenously

Outcome measures

Primary

  • Incidence of AEs with CTCAE Grade≥3 in the escalation phase

    CTCAE: Common Terminology Criteria for Adverse Events

    Time frame: Up to 15 months after 1st infusion in the escalation phase

  • Incidence of SAEs in the escalation phase

    Time frame: Up to 15 months after 1st infusion in the escalation phase

  • Incidence of AEs meeting protocol-defined DLT criteria in the escalation phase

    DLT: dose-limiting toxicity

    Time frame: Up to 28 days after 1st infusion in the escalation phase

  • Incidence of dose modifications due to AEs in the escalation phase

    Time frame: Up to 12 months after 1st infusion in the escalation phase

  • Incidence of AEs leading to discontinuation in the escalation phase

    Time frame: Up to 12 months after 1st infusion in the escalation phase

  • Recommended Phase 2 dose as monotherapy

    Time frame: Up to 24 months after 1st infusion

  • Objective Response Rate (ORR) based on RECIST (v 1.1) criteria in the expansion phase

    RECIST: Response Evaluation Criteria in Solid Tumors.

    Time frame: Up to 24 months after the 1st dose in the expansion phase

  • Duration of Response (DOR) in the expansion phase

    Time frame: Up to 24 months after the 1st dose in the expansion phase

  • Recommended Phase 2 dose in combination with Pembrolizumab

    Time frame: Up to 24 months after 1st dose

  • Incidence of AEs with CTCAE Grade≥3 in the combination phase

    Time frame: Up to 15 months after 1st infusion in the combination phase

  • Incidence of SAEs in the combination phase

    Time frame: Up to 15 months after 1st infusion in the combination phase

  • Incidence of AEs meeting protocol-defined DLT criteria in the combination phase

    Time frame: Up to 28 days after 1st infusion in the combination phase

  • Incidence of dose modifications due to AEs in the combination phase

    Time frame: Up to 12 months after 1st infusion in the combination phase

  • Incidence of AEs leading to discontinuation in the combination phase

    Time frame: Up to 12 months after 1st infusion in the combination phase

Secondary

  • AUC0-last

    Time frame: Predose up to Day 8

  • Cmax

    Time frame: Predose up to Day 8

  • tmax

    Time frame: Predose up to Day 8

  • Objective Response Rate (ORR) based on RECIST (v1.1) criteria in the escalation phase

    Time frame: Up to 24 months after 1st infusion in the escalation phase

  • Incidence of AEs with CTCAE (v5.0) Grade≥3 in the expansion phase

    Time frame: Up to 24 months after 1st infusion in the expansion phase

  • Incidence of SAEs in the expansion phase

    Time frame: Up to 15 months after 1st infusion in the expansion phase

  • Incidence of dose modifications due to AEs in the expansion phase

    Time frame: Up to 12 months after 1st infusion in the expansion phase

  • Incidence of AEs leading to discontinuation in the expansion phase

    Time frame: Up to 12 months after 1st infusion in the expansion phase

  • Disease Control Rate (DCR) according to RECIST (v1.1) criteria

    Time frame: Up to 24 months after 1st infusion

  • Time to Respond (TTR) according to RECIST (v1.1) criteria

    Time frame: Up to 24 months after 1st infusion

  • Objective Response Rate (ORR) based on RECIST criteria in the combination phase

    Time frame: Up to 24 months after 1st infusion in the combination phase

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy * Have a life expectancy≥12 weeks at the time of the screening * Women of childbearing potential must agree to use highly effective methods of contraception for the course of the trial through 120 days after the last dose of trial medication * Males who are sexually active with women of childbearing potential must agree to use condoms and refrain from donating sperm for the course of the trial through 120 days after the last dose of trial medication NOTE- Additional criteria apply, please contact the investigator for more information Exclusion Criteria: * Has a history of systemic treatment therapy for cancer (including chemotherapy, immunotherapy, radiotherapy, or other investigational drug) or surgery within 4 weeks prior to baseline * Is currently receiving or has received hematopoietic colony-stimulating growth factors within 2 weeks before screening or transfusion support 4 weeks prior to screening * Has a diagnosis of immunodeficiency * Has active known autoimmune disease. * Has a history of or known active brain metastases and/or carcinomatous meningitis and/or leptomeningeal metastasis * Has active or uncontrolled serious infections requiring systemic therapy within 14 days prior to baseline * Has a history of clinically significant cardiovascular or cerebrovascular disease in previous 6 months prior to screening * Has evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis * Has a seizure disorder requiring therapy (such as steroids or antiepileptics) NOTE- Additional criteria apply, please contact the investigator for more information

Study locations (11)

Teva Investigational Site 12017

Los Angeles, California, 90025

Recruiting

Teva Investigational Site 12021

Lake Mary, Florida, 32746

Completed

Teva Investigational Site 12016

Chicago, Illinois, 60611

Recruiting

Teva Investigational Site 12015

Detroit, Michigan, 48201

Recruiting

Teva Investigational Site 12014

Huntersville, North Carolina, 28078

Recruiting

Teva Investigational Site 12023

Cincinnati, Ohio, 45219

Recruiting

Teva Investigational Site 12058

Pittsburgh, Pennsylvania, 15232

Recruiting

Teva Investigational Site 12019

Nashville, Tennessee, 37203

Recruiting

Teva Investigational Site 12024

Nashville, Tennessee, 37232

Recruiting

Teva Investigational Site 12018

Fairfax, Virginia, 22031

Recruiting

Teva Investigational Site 12025

Milwaukee, Wisconsin, 53226

Recruiting
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Cancerify